Lilly, Regor partner on metabolic disorders

Dec. 10, 2021

Eli Lilly and Company and Shanghai-based Regor Therapeutics have entered into a multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders.

The deal will allow Lilly to leverage Regor's core technology, a proprietary Computer Accelerated Rational Discovery platform. The tech enables the use of advanced computational tools such as Regor's Virtual Libraries to dramatically accelerate discovery programs. Lilly will use this to focus on breakthrough therapies in obesity and diabetes.

Per the deal, Lilly will be responsible for clinical development, manufacturing and commercialization worldwide, except for People's Republic of China, Macau, Hong Kong and Taiwan, where Regor will maintain these rights and responsibilities.

Regor will receive an upfront payment of up to $50 million and is also eligible to receive up to $1.5 billion in potential payments based on development and commercial milestones.